These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

354 related items for PubMed ID: 20034615

  • 1. Diminished neural processing of aversive and rewarding stimuli during selective serotonin reuptake inhibitor treatment.
    McCabe C, Mishor Z, Cowen PJ, Harmer CJ.
    Biol Psychiatry; 2010 Mar 01; 67(5):439-45. PubMed ID: 20034615
    [Abstract] [Full Text] [Related]

  • 2. Increased positive versus negative affective perception and memory in healthy volunteers following selective serotonin and norepinephrine reuptake inhibition.
    Harmer CJ, Shelley NC, Cowen PJ, Goodwin GM.
    Am J Psychiatry; 2004 Jul 01; 161(7):1256-63. PubMed ID: 15229059
    [Abstract] [Full Text] [Related]

  • 3. Reboxetine and citalopram in panic disorder: a single-blind, cross-over, flexible-dose pilot study.
    Seedat S, van Rheede van Oudtshoorn E, Muller JE, Mohr N, Stein DJ.
    Int Clin Psychopharmacol; 2003 Sep 01; 18(5):279-84. PubMed ID: 12920388
    [Abstract] [Full Text] [Related]

  • 4. Different gender response to serotonergic and noradrenergic antidepressants. A comparative study of the efficacy of citalopram and reboxetine.
    Berlanga C, Flores-Ramos M.
    J Affect Disord; 2006 Oct 01; 95(1-3):119-23. PubMed ID: 16782204
    [Abstract] [Full Text] [Related]

  • 5. Prediction of the response to citalopram and reboxetine in post-stroke depressed patients.
    Rampello L, Chiechio S, Nicoletti G, Alvano A, Vecchio I, Raffaele R, Malaguarnera M.
    Psychopharmacology (Berl); 2004 Apr 01; 173(1-2):73-8. PubMed ID: 14685645
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Reduced neural response to reward following 7 days treatment with the cannabinoid CB1 antagonist rimonabant in healthy volunteers.
    Horder J, Harmer CJ, Cowen PJ, McCabe C.
    Int J Neuropsychopharmacol; 2010 Sep 01; 13(8):1103-13. PubMed ID: 20426883
    [Abstract] [Full Text] [Related]

  • 12. Differential effects of citalopram and reboxetine on cortical Glx measured with proton MR spectroscopy.
    Taylor M, Murphy SE, Selvaraj S, Wylezinkska M, Jezzard P, Cowen PJ, Evans J.
    J Psychopharmacol; 2008 Jul 01; 22(5):473-6. PubMed ID: 18208909
    [Abstract] [Full Text] [Related]

  • 13. Contrasting effects of citalopram and reboxetine on waking salivary cortisol.
    Harmer CJ, Bhagwagar Z, Shelley N, Cowen PJ.
    Psychopharmacology (Berl); 2003 Apr 01; 167(1):112-4. PubMed ID: 12605289
    [Abstract] [Full Text] [Related]

  • 14. In vitro effects of serotonin and noradrenaline reuptake inhibitors on human platelet adhesion and coagulation.
    Hallbäck I, Hägg S, Eriksson AC, Whiss PA.
    Pharmacol Rep; 2012 Apr 01; 64(4):979-83. PubMed ID: 23087151
    [Abstract] [Full Text] [Related]

  • 15. Alpha1-adrenoceptors modulate citalopram-induced serotonin release.
    Rea K, Folgering J, Westerink BH, Cremers TI.
    Neuropharmacology; 2010 Jun 01; 58(7):962-71. PubMed ID: 20043931
    [Abstract] [Full Text] [Related]

  • 16. The norepinephrine reuptake inhibitor reboxetine is more potent in treating murine narcoleptic episodes than the serotonin reuptake inhibitor escitalopram.
    Schmidt C, Leibiger J, Fendt M.
    Behav Brain Res; 2016 Jul 15; 308():205-10. PubMed ID: 27118715
    [Abstract] [Full Text] [Related]

  • 17. Evidence for modulation of facial emotional processing bias during emotional expression decoding by serotonergic and noradrenergic antidepressants: an event-related potential (ERP) study.
    Kerestes R, Labuschagne I, Croft RJ, O'Neill BV, Bhagwagar Z, Phan KL, Nathan PJ.
    Psychopharmacology (Berl); 2009 Mar 15; 202(4):621-34. PubMed ID: 18825371
    [Abstract] [Full Text] [Related]

  • 18. Sex differences in depressive symptoms and tolerability after treatment with selective serotonin reuptake inhibitor antidepressants: Secondary analyses of the GENPOD trial.
    Gougoulaki M, Lewis G, Nutt DJ, Peters TJ, Wiles NJ, Lewis G.
    J Psychopharmacol; 2021 Aug 15; 35(8):919-927. PubMed ID: 33637001
    [Abstract] [Full Text] [Related]

  • 19. Reboxetine versus fluoxetine: an overview of efficacy and tolerability.
    Massana J.
    J Clin Psychiatry; 1998 Aug 15; 59 Suppl 14():8-10. PubMed ID: 9818624
    [Abstract] [Full Text] [Related]

  • 20. Do noradrenaline and serotonin differentially affect social motivation and behaviour?
    Dubini A, Bosc M, Polin V.
    Eur Neuropsychopharmacol; 1997 Apr 15; 7 Suppl 1():S49-55; discussion S71-3. PubMed ID: 9169310
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.